论文部分内容阅读
目的：为了探讨１３１Ｉ标记单克隆抗体Ｃ５０放射免疫显像技术诊断恶性肿瘤的临床价值。材料和方法：３２例疑似肿瘤或肿瘤患者使用１３１Ｉ标记单抗Ｃ５０进行放射免疫显像诊断，全部病例均经手术治疗后病理证实。结果：１３例可疑卵巢癌患者，８例显像阳性，６例术后病理证实，另２例及５例显像阴性者术后病理证实为良性肿瘤，诊断符合率为８４６％（１１／１３）。３例肺癌仅１例显像阳性。５例官颈癌全部显像阳性，１１例乳腺癌患者的腋窝淋巴结显像阳性者８例，７例术后病理证实，另１例及３例显像阴性者术后病理未发现癌细胞。结论：结果表明，１３１Ｉ标记单克隆抗体Ｃ５０诊断卵巢癌、宫颈癌、乳腺癌腋窝淋巴结转移灶有一定临床价值，肺癌显像效果不佳。
Objective: To investigate the clinical value of 131I labeled monoclonal antibody C50 radioimmunoimaging in the diagnosis of malignant tumors. MATERIALS AND METHODS: Thirty-two patients with suspected tumors or tumors were diagnosed by radioimmunoimaging using 131I-labeled monoclonal antibody C50. All the cases were confirmed by pathology after operation. Results: Of the 13 patients with suspected ovarian cancer, 8 were imaging positive and 6 were confirmed by pathology. The other 2 and 5 imaging negative were pathologically confirmed as benign tumors with a diagnostic accuracy of 84.6% (11 / 13). Only one case of lung cancer was positive in 3 cases. 5 cases of cervical cancer all imaging positive, 11 cases of breast cancer patients with axillary lymph node imaging positive in 8 cases, 7 cases confirmed by pathology, and the other 1 case and 3 cases of imaging negative pathology found no cancer cells. Conclusion: The results show that 131I labeled monoclonal antibody C50 diagnosis of ovarian cancer, cervical cancer, axillary lymph node metastases of breast cancer have some clinical value, poor imaging of lung cancer.